How can neurotoxicity associated with CAR T-cell therapy in MM be managed?

The Multiple Myeloma Hub spoke with Peter Forsberg, Colorado Blood Cancer Institute, Denver, US. We asked, How can neurotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) be managed?  In this interview, Dr Forsberg explored the evolving understanding and management of neurotoxicity associated with CAR T-cell therapy in MM. Forsberg highlighted current strategies for managing these toxicities and identifying patients at higher risk, concluding by emphasizing the importance of collaboration among healthcare professionals to refine diagnostic criteria and optimize therapeutic interventions as CAR T-cell therapy becomes increasingly integrated into the MM treatment paradigm. This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.  Hosted on Acast. See acast.com/privacy for more information.